Statin diabetogenicity: guidance for clinicians

Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy

(2012) Alfonso Bellia et al.   ATHEROSCLEROSIS

Statins are diabetogenic – Myth or reality?

(2012) Naveed Sattar et al.   ATHEROSCLEROSIS SUPPLEMENTS

Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men

(2011) S. Goya Wannamethee et al.   ARCHIVES OF INTERNAL MEDICINE

Randomized Head-to-Head Comparison of Pitavastatin, Atorvastatin, and Rosuvastatin for Safety and Efficacy (Quantity and Quality of LDL)

(2011) Keijiro Saku et al.   CIRCULATION JOURNAL

Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy

(2011) David Preiss   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Influence of Pitavastatin on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus

(2011) Tadashi Yamakawa et al.   Journal of Atherosclerosis and Thrombosis

Influence of Statins on Glucose Tolerance in Patients with Type 2 Diabetes Mellitus: Subanalysis of the Collaborative Study on Hypercholesterolemia Drug Intervention and their Benefits for Atherosclerosis Prevention (CHIBA Study)

(2011) Koutaro Yokote et al.   Journal of Atherosclerosis and Thrombosis

Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin

(2011) David D. Waters et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

New evidence on pitavastatin: efficacy and safety in clinical studies

(2010) Tamio Teramoto et al.   EXPERT OPINION ON PHARMACOTHERAPY

Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients

(2010) Kwang Kon Koh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

Comparison of 80 versus 10 mg of Atorvastatin on Occurrence of Cardiovascular Events After the First Event (from the Treating to New Targets [TNT] Trial)

(2009) John C. LaRosa et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

(2009) Kausik K Ray et al.   LANCET

Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis

(2008)   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE